Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Viking Therapeutics Fourth Quarter and Full-year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Following management’s prepared remarks, we will hold a question and answer session. [Operator Instructions] As a reminder, this conference call is being recorded today, February 8, 2023.

I would now like to turn the over to Viking’s Manager of Investor Relations, Stephanie Diaz. ahead. go Please

Stephanie Diaz

you thank participating today’s in Hello all call. and for

is Joining President Brian and today CEO; CFO. Viking’s Viking’s Lian, me Zante, and Greg

made lines Private Forward-Looking about its Statements I caution the including safe today, begin, statements like of under and Reform X, during the development Act provisions comments XXXX, U.S. February contain we regarding call Litigation this activities, Viking’s will Before XXXX, milestones. expectations harbor time conference Securities would that to of

encourage that uncertainties results and cause risks and considered to obligation and only subject are and performance. of undertakes no reported all the the update the to statements to as Company’s results and date, filings as any and matters. future Company materially speak should could these differ to today. forward-looking of Forward-looking actual concerning you be Exchange statements These Commission of an with review adversely or indication not today’s I Securities other revise statement made

now turn I Brian his the for to will comments. initial call over Lian

Brian Lian

to an with good and quarter we or Today, phone on Stephanie, financial listening recent and on and by in programs webcast. everyone review XXXX provide for full-year dialed the the and our results our fourth clinical update progress will Thanks, operations. afternoon

data enrollment this XXXX. announced an of expect VOYAGE and recently in VKXXXX, we second was our of drug expanded advanced announce year and fibrosis, completion lead the quarter study clinical to from treatment Phase we exciting With pipeline XXXX to respect and line for for each development our three we NASH trial, in top of IIb our as Viking programs. of our candidate the

agonist of our trial I newest GIP GLP-X the is continuing. potential metabolic treatment Phase the and for program, the addition, VKXXXX dual disorders evaluating In receptor

this from quarter. to later data this expect report the initial trial We

also later X-linked expect And finally, treatment for this this to complete study clinical enroll adrenoleukodystrophy Phase trial Ib we VKXXXX to year. continues of evaluating the the and

disorders, look strengthened after year. data novel each position in activities to the we and Viking’s the operations on I our development significantly we advancements XXXX clinical metabolic this as financial details of development fourth review clinical results. provide leader further and quarter will of reporting for forward programs therapeutics of class-leading have Our and our three full-year a these from treatment

With I Zante, to the Officer. Chief turn that, will call Greg over Viking’s Financial

Gregory Zante

comments, Thanks, and I Securities Viking’s expect shortly. recommend my would participants to we file which Brian. Exchange that conjunction In refer XX-K like with to filing with Commission, Form to the

quarter quarter. go XXXX, and now results beginning XX, for will the I over full-year results the fourth ended for with December the our

Our the $XX.X research and period development expenses XX, $X.X were December for ended same million to compared for the XXXX. three in months million XXXX,

salaries preclinical The expenses stock-based primarily to decreased benefits, and increase due for to related clinical manufacturing to and related studies, increased compensation by candidates, studies, drug Company’s was consultants. offset partially third-party the expenses

partially Our increased to The compensation general for $X.X XXXX, due related third-party by consultants. December legal primarily salaries to million and to administrative XXXX. was compared million benefits increase in decreased were expenses for XX, and offset $X.X same period expenses the three the stock-based months and services, related to ended expenses

or the million XXXX. loss $X.XX in or period three net the For December reported Viking corresponding share compared XX, to $XX.X months a a loss of per of ended XXXX, million in $XX.X per net share $X.XX

XXXX, same for to of share general in noted and the due net development December net months primarily research and and to compared the increase the The administrative was previously period increase XX, XXXX. three loss ended and expenses in loss per

I go will the for over XXXX now results year. fiscal full

period for million compared XX, December XXXX. the $XX to XXXX, research same the development were for expenses in Our and million year $XX.X ending

offset salaries and by increased Company’s decreased and drug compensation, The related partially third-party candidates, expenses for manufacturing to and to related increase studies, expenses to the due preclinical clinical was stock-based consultants primarily studies. benefits

Our $XX.X expenses insurance period to for $XX.X salaries related to and million general December partially professional consultants. benefits compared legal services, was ending offset XXXX, year and decreased primarily related were same to third-party compensation, for due expenses in expenses the increased the services XXXX. stock-based million XX, and administrative and The increase by to

a XX, the the million compared or of reported For share in per $X.XX year of December $X.XX ending $XX corresponding a in XXXX, net XXXX. share or loss Viking $XX.X per million loss to period net

previously. the noted net administrative ended to general loss as due XX, and December expenses, increase was increase development in The per the in for primarily and XXXX, year net and loss share research

Turning equivalents XXXX, totaling $XXX $XXX cash, to December million XXXX. XX, million to compared investments XX, sheet. of At the Viking cash held December balance and short-term as

and financial call will back my Brian. over the turn to review, concludes This I now

Brian Lian

Greg. was we for year expanded footprint and development Thanks, our XXXX clinical programs. progress exciting Viking continued existing our made an with as

Viking disorders, we XX-months, past our internally but new a addition not only existing program VKXXXX. in expertise metabolic with the developed the Over announced two clinical on building clinical advanced of its programs,

I with the molecule NASH compound, will beta orally for our and the isoform available of the that agonist provide thyroid overview is now tissue as well of as progress VKXXXX, of beginning VKXXXX three liver fibrosis. these our with lead selected of small for programs, hormone receptor. an an receptor each is

to for of unique that activation data patients with NASH therapeutic the the a beta indication. as and this thyroid point date to provides best-in-class believe benefits VKXXXX receptor hormone We for therapeutic

demonstrating fat trial fatty of in patients promise hypercholesterolemia lipids. Data liver from reductions XX-week successfully support disease, in plasma liver prior and significant and Phase achieved the both and with primary and its This IIa trial endpoints nonalcoholic VKXXXX. the Company’s secondary

mean demonstrated reductions at liver that content experienced receiving reduction to that relative VKXXXX liver XX% experienced fat a and VKXXXX fat XX% with relative of XX% up patients treated cohorts in least content. trial the of Further,

fat completion the remaining VKXXXX. Importantly, patients study dosing. after tolerability majority four-weeks durable and profile were the promising with This in also the liver of reductions responders of of demonstrated safety

VKXXXX-treated to patients and disturbances reported placebo. and was with were of events patients the rate lower compared nausea as adverse such serious when No treated GI among diarrhea

of all been proteins, risk. one of triglycerides lipids, its LDL unique with most have cardiovascular of features including plasma VKXXXX Perhaps and effect which distinguishing atherogenic the is cholesterol, on correlated

Various studies programs patients these plasma robust other elevation Viking’s Phase suggesting these comparison, VKXXXX in study may following of reductions evaluating XX-week in that demonstrated development a experienced benefit. lipids, have By treatment. IIa NASH cardioprotective offer lipids

as these route of broad all lipid-lowering oral reduction of reasons, believe administration, excellent combined drug a treatment fat safety, VKXXXX’s establish its NASH. leading For we tolerability significant candidate and with for liver and the of it properties

and IIb study. evaluate biopsy-confirmed of completion successful our Phase Following A trial trial, VKXXXX fibrosis. to Phase Viking initiated patients with the NASH designed VOYAGE IIa in

international a multicenter assess the double-blind, efficacy, with randomized, trial VKXXXX designed and placebo-controlled, patients of NASH to and safety is biopsy-confirmed fibrosis. tolerability VOYAGE in

as XX% fat may liver density FX The target with fibrosis patients Up of imaging also risk fat includes have least provided well one as as fibrosis. possess proton measured least resins magnetic at that at patients FX by they population to FX fraction X% factor. content and additional

the VOYAGE change of content in endpoint fat week evaluate will liver from receiving XX to VKXXXX to primary in the patients patients placebo. baseline study as with The compared treated

treatment. by histologic evaluation XX the hepatic of weeks of after include biopsy changes objectives Secondary

top in Earlier line this the of we VOYAGE, and this sharing completion announced quarter, to second during forward enrollment endpoint of trial’s quarter year. results, primary we including the look

VKXXXX our obesity, the will treatment potential research, design VKXXXX from NASH disorders, metabolic I on our promising with rare in-house as leveraging diseases. potential. certain new update of therapeutic provide and newest such various and arose our now expertise an evaluate clinical for to internal metabolic candidate, compounds

at glucose-dependent activation achieved and of the This alone. data GLP-X demonstrated in like the peptide-X, insulin effects of or Annual atrophic the through GLP-X the agonist compound XXXX is program receptor the of receptor glucagon activity upon GIP presented Obesity Initial that receptor. this GIP Meeting the a improved polypeptide, or dual metabolic Society from receptor

compounds Specific observed in as included following among when time. findings a treatment obese glucose the dose monoagoist period insulin GLP-X with weight administered loss, for compared at control same to diet-induced mice of improvements the and same sensitivity Viking

fat a with the GLP-X relative observed larger observed treated generally our monoaconist. reductions among animals fat addition, animals content among In in the liver with treated compounds were to liver reductions

initiation study. announced trial Phase is VKXXXX. trial double-blind, ascending Viking placebo-controlled, I single of a XXXX, In a and randomized, dose ascending of the clinical This multiple

study a adults the enroll square. designed ascending dose designed while adults multiple dose is portion The the minimum to body healthy per is with meter index XX mass ascending single to healthy enroll portion kilograms of of

The of delivered the study doses. single of of include following objectives an as subcutaneously also identification of development. VKXXXX single will the safety of Primary multiple evaluate VKXXXX the trial and tolerability for of clinical and evaluation multiple further as doses doses suitable pharmacokinetics well and

this ongoing, after include quarter. fat Exploratory four results of expect pharmacodynamic liver to in is and and assessments administration. weeks body This weight report initial changes later content of once we weekly evaluations study

Our patients in is available or clinical Phase thyroid in with X-linked small which third orally a clinical second Ib currently candidate is VKXXXX X-ALD. evaluated receptor VKXXXX, molecule adrenoleukodystrophy trial is in hormone X-ALD chain long Viking’s is mutations clinical acids. often a genetic fatal the disorder by beta function of metabolic caused very impact and peroxisomal agonist fatty that rare transporter of development. being

result The clinical compounds onset is impaired of patients with mutations, efficiently As patients the of in resulting and and metabolize of a transporter accumulation the fatty are X-ALD. function and is chain to to these contribute acids. believed long symptoms very signs unable to progression

consistent than no demonstrated XXX evidence accumulation prior received XX-day VKXXXX in a lipoprotein a half-life triglycerides, and dosing. experienced B In of exposures, cholesterol, with anticipated in apolipoprotein LDL once-daily study more reductions and Phase who Subjects VKXXXX I healthy dose-dependent volunteers, A.

observed side and or effects, VKXXXX’s No demonstrated no reported, tolerability. measures. events also were vital and safety study were GI dose-related serious for encouraging signs treatment or This cardiovascular signals adverse

VKXXXX is I affecting of of Ib completion most common AMN XX% Phase patients of of of approximately with the initiated those the with form Viking X-ALD. or Phase X-ALD the in form disease. AMN Following adrenomyeloneuropathy study, the the study

study patients AMN. VKXXXX The of are male for administered to of is safety the orally objectives placebo-controlled tolerability the and in Phase a Ib multicenter primary adult XX-days. evaluate The daily study double-blind, trial once randomized, with

of evaluation of acids. the may includes report long-chain well pursued. expect of results study of The a an later be year. also cohorts study AMN preliminary to dosing blinded data, additional as initial Pending exploratory review and in the we as fatty in assessment plasma changes levels to patients VKXXXX pharmacokinetics enroll, very an continues this of This

Turning to financials.

$XXX programs cash that Greg million Our currently cash. R&D sufficient in our with our balance year current into XXXX approximately each in We overall We with the development. anticipate we runway our approximately And later-stage advance clinical believe our R&D in strong. be of provide XXXX as will sheet expenses. resources expenses line remains completed discussed, to

company to with accelerated on program Building XXXX. a VKXXXX, Viking advancing lead candidates our has past initial of couple company closing, in In metabolic range with transformation that which program, three a for significant taken the emphasize has distinct I indications. success of over place our clinical at wish a single clinical evolved the Viking to years, from a

three In to from report XXXX, data enrollment trial, each to report treatment second expect the we and and fibrosis, IIb to data the for these expect completed we respect Phase VKXXXX now we quarter. programs. With of in have our of initial VOYAGE NASH in clinical

Our later we study report GLP-X trial expect expect I this quarter. to VKXXXX the to this report to Phase GIP study our and dual the we ongoing, continues evaluating trial from and year. Phase in X-ALD And from data is evaluating agonist VKXXXX patients later data Ib this this enroll, initial

Operator. This and we now open Thanks us, joining today. concludes for comments questions. call again the prepared will for for our

Operator

Our begin first from ahead. now Instructions] will the [Operator Lee will Joon Please question-and-answer We go question Truist. session. of come

Joon So Lee

our five-cohorts Have stated for across I’m asking subjects and XX maybe enrollment and date December. in According for because Thank is you. estimated the study completion target healthy the clinicaltrials.gov, add Part to cohorts? XXXX more enrollment B. target just you for questions updates. for A six-cohorts the volunteer now your Thanks exceeded in Part is taking as the and/or

Brian Lian

anything. didn’t Joon, No, for any we slower is we we prolonged question. would cohorts. little nothing. haven’t just the additional haven’t thanks - Hey like, We than It a there is added but

Joon So Lee

And or have enrolling the volunteer for thing? healthy completed are now you you enrollment still

Brian Lian

a have we mind in the keep window. have quarter. XX-day what treatment, got then follow-up the to we - is a, said We But you there and is haven’t XX-days is said results believe, will this I of trial that

So a window there. long it is

Joon So Lee

female or it one multi-dose Are male the men? Okay just and and both you last portion question. is enrolling for

Brian Lian

It is both.

Operator

Seedhouse Raymond next go question Steven of comes ahead. from James. Our Please

Steven Seedhouse

couple, a thanks the afternoon, lot Good first Just ask for taking questions, a to XXXX. on wanted

dose laboratory escalation decisions the on it serum data escalation at goes are the that assess meetings, the SRC or something triglycerides that dose activity. safety laboratory would pharmacodynamic just wanted to decision, into to - it data. is So guess based looking is and safety I I on just confirm, they all like include

Brian Lian

it it safety-driven measures is They and well, on have PK safety pretty determination. as is efficacy. pretty pharmacodynamic much really a No, much any not but

Steven Seedhouse

just And Okay. to question. parlay of

you portion end or enrolling the less five than in was five did So cohorts it fully cohorts up MAD ultimately?

Brian Lian

Well, It we been. many ongoing is how have said exactly haven’t now.

disclosed yes, Steve. So haven’t that, we just

Steven Seedhouse

Okay. look at the more that on receptor us I’m to I’m specifically of on Maybe these is variables. molecule, you compare targets. on the and the Can if GLP-X native versus isolate in or that - activity. in, that equipotent peptide pharmacology GLP-X lot you on native you across less folks including isolation, digging activity two or there curious, of just comment relative to GLP-X? activity Are trying a

Brian Lian

Yes. That question. is a good

less on just these most ours, compounds, GLP-X. of are potent them of most I think but not

that the don’t one numbers recall on we to are close of semaglutide. pretty and was top are we looked think receptor pretty on off the darn at my semaglutide, head, but that. I I most similar the we

Steven Seedhouse

And Yes. to Okay. hepatitis as well.

is that So interesting.

just And TR Okay. mechanism then Beta, focus on lots these that of obviously, days. on

just selection the have dose in again the lately getting study. We been questions on VOYAGE

or than hoping just So articulate lower optimize in you was Phase of what for doses including window prior this aspects Are could testing of the the therapeutic series key mechanism. doses, IIa aspects by I trying study? a you to

Brian Lian

Yes, yes.

cohorts, Phase changes they day, There at we all five-mg look XX-mg looked we the those the So three at XX-mgs - day the And of data, II lipids, a XX-week data, prior when every and things. study, efficacy pretty looked data, similar. all were kinds other the the the daily. in of all

right the dose Maybe it response And the so us. it is incorrect, what but on far of to is curve. were suggested that like looked certainly we sort that of that

minimally that had FDA dose we dose. likes that to always felt the have on the we effective down so know a is. come handle And to in And room we what

back looked starts Phase looked to it and the when what like that And is lipids. was so dose one-milligram we affecting like data at at prior you look look studies I it

thought And the probably be so minimally dose. that, we that effective would

day, XX-week And other the rationale. spread of to dose And daily. we of the XX-mg out we up we every dosed which top include the but XX-mg that was overlapping equal And to five-mg there a then just between it thought study. was the and largely from kind that with daily those, was

Steven Seedhouse

Brian. Thanks Thanks the for questions.

Brian Lian

Steve. Thanks

Operator

comes question Please of Joe Wainwright. Pantginis The go ahead. from next H.C.

Joseph Pantginis

assets. it guys, two but III towards Hey community question, question. good their taking two early trial on understanding clinical is for this afternoon, different Phase the different a TR traction XXXX, gaining has too thanks the ask you and in beta look Brian, I obviously, with fronts don’t potential as think with to been for

study? your being to So you enroll what patients a I considering guess or other are you with asset how little pivotal to say, mature, the into for more competition of handle would things consider regarding, kinds

Brian Lian

that mechanism. with an characteristics. GLP-Xs, to with space Phase there is those approved are the have agent are GLP-X in of And think enrolling enough that I seen share enroll the even multiple studies if diabetes III and that trials there there same indications there still agonists other Well, plenty the in out past we approved patients

to It there. So - significant but enroll anyway. will I competition enroll hard circumstances, to under hard the any is I problem think don’t be hard a mean a NASH is just side

Joseph Pantginis

Sure, very helpful, thank you.

Brian Lian

Joe. Thanks

Operator

Olson comes go Oppenheimer. question Please next The Jay from of ahead.

Unidentified Analyst

on us. couple for Congrats the from line Maybe on [indiscernible] is this Hey Jay. progress. the a

on First XXXX.

of were Phase the events IIa lower groups. GI you or toxicity the I the showed think treatment study, actually in in adverse

follow-up the have the to just we a a maybe GI in property and study for do liver XXXX So to XXXX targeting I And that, to you XXX. related maybe future? is something the the combine in maybe expect if out to see this with related should tolerability of play how remind all forward path to us can and you AD GLP-X

Brian Lian

respect like the Yes, one haven’t that question different XXXX and it be we the the I seen with necessarily tolerability, combined that studies. the to could is it a of just any oral second because of something seen. haven’t those. I be Yes, GLP-Xs just And GI With to know don’t we in think answer of liver-targeted prior variety could first. anything is compounds

Unidentified Analyst

a XXXX, question, Okay, initiated just a of thanks and the were like year. second cohorts I following for previous maybe there know was few maybe dose in half last

or from should data only cohorts of So expect wondering, we the for cohorts? readout, some the all see upcoming Thanks. just to

Brian Lian

everybody It than us, kind up Yes. a well. We of the that know including little then been bit that all the like, as cohorts I hope And of it been a to - of have split. got broke slower had couple would cohorts. from the data is holidays has we

I if since patients day. not it Phase available to unit, they is the is a in come And have necessarily day a next miss

But has from just the quarter out that the So all of cohorts. dragged we some the believe have this we data will do cohorts.

Unidentified Analyst

the again question. Thanks for taking Okay.

Brian Lian

Thanks.

Operator

The Please Hsieh go next Andy ahead. comes William question from of Blair.

Andy Hsieh

Thanks for taking our question.

obviously, of recently. space NASH So lot is movement a the in there

Just perspective? in to terms that curious from leading about the of magnitude of correlation fat or and thinking between your the liver histological a fibrosis reduction

Brian Lian

Yes. Thanks, Andy.

weight correlation well-established and fibrosis, think shown in in fats that histology, has there in but are is exceptions. improvement overall reduction been it loss I studies pharmacological including studies. between also fairly in But and liver

on liver have appear most why improvement. mechanisms don’t There NASH reduction, shown in reduce fat to higher particularly you relative resolution you haven’t XX% would that them fat, that liver success and I above the of histologic when And is. other fibrosis are know odds - that But reduce show resulted and been some of improvements. to have

Andy Hsieh

is Got helpful. it. That

dozen looking Phase the just from I as thing kind selection. potential in-house or be for disease versus - XXXX, also and program, diseases? to so Going if rare I’m might of potentially whole, there is for is special indication same characteristics would anything you compounds, SAD/MAD readout development forgot, indication, curious like a half bigger I maybe curious about the position good well advance saw candidates that at other sort any a a the your you other for right? unique study maybe that that XXXX you assets, to There presented. that the of And you on as there specific anticipate metabolic I’m

Brian Lian

question, good a Yes. That is Andy.

of have a whole early We have we us make discovery is part system used of helped And at compounds different which sort bunch kind the guide And work. we of that scoring to that to looked have peptides. prioritize. a explore continue of and these, that the to on that kind we of some and decisions has

And efficacy we the prioritize. PK and look help at to models then in-vivo data,

indications. As far I globally, then as couple for opportunities the mechanism, indications smaller the diabetes of think you just NASH, to obesity look at when it and the select, is a

like XXXX and opportunities beta we And thyroid the in of the we have look to agonist would like the and with then VKXXXX orphan view bigger kind a opportunity, NASH where indication. at we got

if something will had that be agonist, dual pursuing able in ideal. large would think we the that I in be and with we I a a to think parallel molecule we as indication, that were forward. we indication move different smaller And and

Andy Hsieh

all answering for our questions. thanks Great, of

Brian Lian

Thank you, Andy.

Operator

question of Jen comes from Yale Laidlaw Co. & Please go The ahead. next

Yale Jen

questions. afternoon and taking Good for thanks the

top give additional me a this on view to pending in make outcome. Thank do nevertheless, release the that, data what of you XXXX, would data some In sort possibly quarter? you will the release, after decisions terms you that we of and you. and obviously, understand after anticipate But

Brian Lian

completion to this U.S. hope would we following an IND the Well, in pursue Yale. Thanks, study. of Yes.

then around that once more by have time would II midyear And we from we plans so release point information data. And sometime and around the there. details I proceed we the Phase the and to Phase for will pursue hope

Yale Jen

appreciate Okay, it. I great. Thanks and

Brian Lian

Thanks Yale.

Operator

The next Scott ROTH of go Henry from question comes ahead. Capital. Please

Scott Henry

afternoon. good Thank you and

Just a couple of questions.

cadence How spending relative XXXX a as we the earlier higher First, the as in think should about year throughout quarter was the far the spending And year. in quarters? to in than perhaps XXXX? the little

Gregory Zante

R&D comment, Brian, expenses we Hey make comments will pretty the think did Scott, earlier did be the in that I consistent. our

XXXX XXXX the in total versus in expect year. We for

those So drive expenses R&D our think of I spending, most the do.

So with about lining spending I pretty expenditure. guess R&D closely we our our up could think

- I So are if that we we pretty think. at consistently, look

Scott Henry

any Okay. And through the we in? well, should consistent as trends year factor

Brian Lian

evenly plans say ahead. I pretty the looking No, the would throughout just year, at

would evenly. I say yes, pretty So

Scott Henry

with Brian, and big-picture that question. Okay. of Great. options assets company to is these the valuation in keep last that strategy Clearly, Does the forward sort going how the available terms has long you of helpful. of months. perhaps are you? That development, some of And changed the just a over them impact your

Brian Lian

Scott, well, not really.

and indications some And our We at involved that to like said beyond. look preference. have always these in it a that would be larger NASH preferable of Phase when large we have is party still III

market our I you yourselves. have later-stage a cap to more But opportunities the studies. think might to preference things change have as that in changes, do doesn’t involved partner

Scott Henry

anything Great Okay. to a there straightforward profile is in market. obesity XXXX, obviously, make but or in worse regards market, there? certainly or safety a similar mean, agents indication just safety question, I than right that expected Is now final your more very is profile would better out diabetes it obesity. your and hot significant with

compares class it how to agents. similar wondering Just other

Brian Lian

a to challenge Yes, think is it on differentiate. tolerability, I

can is the aware If I is with of get seems the it first are through to happens from help, And and that it mechanism It you titration because patients think both past early. you and of the of receptor month GLP-X tolerability and to that nausea hard dosing, issues. clinicians modulate probably that those extricate plus you if generally are so efficacy transient. two then most or is

you if you going agents weight, confident just receptivity think acceptance tolerability the loss. is they weight big to are I feature And is profound that these that and differentiating at lose is or of - induce of least are issues there to

know will you okay and is it accept think when to they are they weight. I separate given to it tolerability is if the So this I mechanism, on patients think lose most going hard it have familiarity but

Scott Henry

taking for questions. you Thank the Okay.

Brian Lian

Scott. Thanks

Operator

comes from ahead. of question go Justin next BTIG. Zelin Please The

Justin Zelin

the add on question congrats for guys Hey question taking and on the progress. I a XXXX. thanks will

you Do longer looking be or here So at a able you to think you period do on efficacy start some see going in probably will some you signs be time weeks tolerability, look weight drug you are loss? and PD to need PKA think obviously, of here. to at will four seeing to that safety,

Brian Lian

Hey Justin, that is a question. great

think I weight see hard really is XX-days loss to in.

we take are of be to So us tolerability, forward sort we II going at informing what regimen most a Phase looking into PK for study.

When of think we if look at are the monoagonist, potential I can of we that think a hurdle that looking interest there similar pretty pharmacodynamic show measures, the would body the really be weight to greatest at I GLP-X we And is people. is exciting. looks efficacy

activity generally, And would the that, GLP-X that because GLP-X, but we going know from augment the are not clear to is don’t course hitting GIP sub-X% that, observable XX-days. the in see XX-days. a just observed We X% be to over is that we in to know separation whether and going we exciting X% is is treatment short we range, as know fully that in that we feel believe monoagonist, of we that be animals, and or or a

conservative the is expectations trying there on for are short such we to a efficacy So study. since be pretty it

Justin Zelin

the Thanks Great for that question. makes for me. taking sense

Brian Lian

Justin. Thanks

Operator

Naz Rahman from question next comes go Maxim Group. Please ahead. of The

Nazibur Rahman

kind what shifting walk little sort in of What of expected this Hi year, us just question. through you And on kind study you could the but a I focus had a bit. are my hoping I guys, thanks what the for? or later of see to taking looking XXXX data are you for few, will

Brian Lian

it going be - study. Ib a Yes. With to are looking this study, Phase we is

in really encouraging healthy tolerability study look We saw the they pharmacodynamic will adrenoleukodystrophy. and at population. safety have So and but shorter PK we and in tolerability in effects patient volunteers, didn’t

patients. any in look the main disease acids, we in will very focus. of the course of long are see are pharmacodynamic if will be we fatty to chain look So on and Those at which PK side, to at changes contribute these the believed differences. areas And will there

Nazibur Rahman

patients? you biomarkers could are looking you Just any us, at these notable like remind in

Brian Lian

Yes.

I at tie would as very think key looking chain would be be Yes. fatty the we marker long there.

Nazibur Rahman

Okay. Got it.

remind you could third cohort the study also study? you the the us if in on On line, plan enrolling

Brian Lian

dosing may cohort. cohorts placebo the to not make cohort. or a enough Well, add And a decision, we when now. have is we Oh, dose we XX. have then a It three and higher XX third and may data

Nazibur Rahman

when release it. going three the you are have to are Got wait ones? you separately all release until from you going lease from the the core to data, And cohort you or data just data or

Brian Lian

It is a design. parallel

really we data So solve would together. the

Nazibur Rahman

answering thanks for got it. my Okay, questions.

Brian Lian

Thanks Naz.

Operator

would question-and-answer the over our like This Diaz remarks. concludes session. turn I for to conference back closing any Stephanie to

Stephanie Diaz

again again Viking participation you and you your for We coming Thank forward updating look support of in months. to great the continued Therapeutics. Have a afternoon.

Operator

disconnect. you The conference has and may now presentation, concluded. Thank you today’s for attending now

Viking Therapeutics (VKTX) 8 Feb 232022 Q4 Earnings call transcript